Trial site
The Retina Institute
St Louis, Missouri 63128, United StatesNot linked to an institution yet
- 17running trials
- 5closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 13 trials
- Phase 1/23 trials
- Phase 23 trials
- Phase 2/33 trials
- Status
- Active, not recruiting11 trials
- Recruiting5 trials
- Completed4 trials
- Not yet recruiting1 trial
- Terminated1 trial
- Lead sponsor
- 4D Molecular Therapeutics3 trials
- Kodiak Sciences Inc3 trials
- EyePoint Pharmaceuticals, Inc.2 trials
- Genentech, Inc.2 trials
- Hoffmann-La Roche2 trials
- and 8 more
Running trials
Recruiting
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
NCT07867080· Phase 3· 4D Molecular Therapeutics· Source
Contact: 4DMT Patient Advocacy
Active, not recruiting
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445· Phase 2· ONL Therapeutics· Source
Contact: Study Coordinator
Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
NCT06990399· Phase 3· Kodiak Sciences Inc· Source
Contact: Kodiak Sciences Inc
Recruiting
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT07064759· Phase 3· 4D Molecular Therapeutics· Source
Contact: 4DMT Patient Advocacy
Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
NCT06996080· Phase 3· Kodiak Sciences Inc· Source
Contact: Kodiak Sciences Inc
Active, not recruiting
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988· Phase 3· 4D Molecular Therapeutics· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918· Phase 3· Ocular Therapeutix, Inc.· Source
Active, not recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT06556368· Phase 3· Kodiak Sciences Inc· Source
Active, not recruiting
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
NCT05904028· Phase 3· Jaeb Center for Health Research· Source
Active, not recruiting
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
NCT06018558· Phase 1/2· Ocugen· Source
Active, not recruiting
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
NCT05956626· Phase 2/3· Ocugen· Source
Active, not recruiting
Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
NCT06087458· Phase 1/2· Perceive Biotherapeutics, Inc.· Source
Recruiting
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
NCT05626114· Phase 2· Genentech, Inc.· Source
Active, not recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
NCT06847854· Phase 1· Genentech, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error